On Monday I was finally able to start the clinical trial Everolimus for patients with relapsed/refractory germ cell cancer (RADIT), and I’m now looking forward to recruit the first patient. We aim to treat 25 patients with cancer of the testis with the mTOR inhibitor everolimus in this phase II trial, and eight German hospitals are participating.